Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Impax Laboratories Inc (NASDAQ:IPXL)

13.65
Delayed Data
As of Dec 02
 -0.10 / -0.73%
Today’s Change
12.45
Today|||52-Week Range
45.00
-68.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$1.0B

Company Description

Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture and marketing of controlled-release and niche generics. It operates through the Impax Generics and Impax Specialty Pharma segments. The Impax Generics segment concentrates on the development manufacture, sale and distribution of generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Impax Specialty Pharma segment engages in the development of proprietary brand pharmaceutical products. The company was founded on December 14, 1999 and is headquartered in Hayward, CA.

Contact Information

Impax Laboratories, Inc.
30831 Huntwood Avenue
Hayward California 94544-7003
P:(510) 240-6000
Investor Relations:
(215) 558-4526

Employees

Shareholders

Mutual fund holders47.61%
Other institutional38.07%
Individual stakeholders12.93%

Top Executives

George Frederick WilkinsonPresident, Chief Executive Officer & Director
Andrew SchaschlSenior Vice President-Global Operations
Bryan M. ReasonsChief Financial Officer & Senior VP-Finance
Vishal K. GuptaCSO, Senior Vice President-Research & Development
Deborah M. PenzaChief Compliance Officer & Senior Vice President